Equities

Viemed Healthcare Inc

Viemed Healthcare Inc

Actions
Health CareHealth Care Providers
  • Price (USD)8.67
  • Today's Change-0.04 / -0.46%
  • Shares traded43.27k
  • 1 Year change+10.87%
  • Beta1.4699
Data delayed at least 15 minutes, as of Nov 22 2024 16:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Viemed Healthcare Inc have a median target of 12.50, with a high estimate of 15.00 and a low estimate of 11.00. The median estimate represents a 43.51% increase from the last price of 8.71.
High72.2%15.00
Med43.5%12.50
Low26.3%11.00

Earnings history & estimates in USD

On Nov 06, 2024, Viemed Healthcare Inc reported 3rd quarter 2024 earnings of 0.10 per share. This result exceeded the 0.08 consensus of the 2 analysts covering the company and exceeded last year's 3rd quarter results by 42.86%.
The next earnings announcement is expected on Mar 04, 2025.
Average growth rate+30.75%
Viemed Healthcare Inc reported annual 2023 earnings of 0.25 per share on Mar 06, 2024.
Average growth rate+56.25%
More ▼

Revenue history & estimates in USD

Viemed Healthcare, Inc. had 3rd quarter 2024 revenues of 58.00m. This bettered the 57.15m consensus of the 2 analysts covering the company. This was 46.64% above the prior year's 3rd quarter results.
Average growth rate+4.15%
Viemed Healthcare, Inc. had revenues for the full year 2023 of 183.01m. This was 31.82% above the prior year's results.
Average growth rate+31.82%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.